Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More

Summary

Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. This randomized, observer-blind, placebo-controlled, adaptive phase 1 trial aims to evaluate the safety and immunogenicity of an investigational zoster mRNA vaccine in healthy participants aged 40 years or more.

Timeline

Start

2025-05-10

Primary completion

2025-12-10

Completion

2026-11-10

Drugs

Indications